Merck kick-starts PhIII cholesterol trials for its oral PCSK9; Baxter recalls 13,000+ vials of chemotherapy

Mer­ck re­vealed Fri­day it start­ed up its first late-stage clin­i­cal pro­gram for an oral PC­SK9 in­hibitor for cho­les­terol.

The pro­gram is cur­rent­ly en­rolling par­tic­i­pants in two reg­is­tra­tional stud­ies for MK-0616, which aims to low­er LDL cho­les­terol. An out­comes study is al­so set to start this year, with plans to en­roll a com­bined 17,000 pa­tients be­tween all three tri­als.

The reg­is­tra­tional tri­als are ex­pect­ed to wrap up in 2025, and the out­comes study in 2029.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.